Precise evaluation of chemotherapy-induced peripheral neuropathy using the visual analogue scale: a quantitative and comparative analysis of neuropathy occurring with paclitaxel–carboplatin and docetaxel–carboplatin therapy

Takemoto, Shuji; Ushijima, Kimio; Honda, Kazumi; Wada, Hiroyoshi; Terada, Atsumu; Imaishi, Hiroto; Kamura, Toshiharu

doi:10.1007/s10147-011-0303-6

Cited by 16 publications

(12 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This higher incidence of pain was attributed to the systematic collection of pain data, suggesting that assessment of neuropathic pain is a necessary development for CIPN PROs. The VAS scale for neuropathy or pain has been utilised in several CIPN studies but still remains to be fully validated and compared to other assessment tools. Similarly, the neuropathic pain symptom inventory, which is primarily a VAS‐based rating system comprising four subscales and 12 items, has been validated in Chinese with good reliability .…”

Section: Resultsmentioning

confidence: 99%

Overview and critical revision of clinical assessment tools in chemotherapy‐induced peripheral neurotoxicity

Park

Alberti

Kolb

et al. 2019

J Peripheral Nervous Sys

View full text Add to dashboard Cite

Chemotherapy-induced peripheral neurotoxicity (CIPN) is a major toxicity of cancer treatment, leading to dose reduction and premature treatment cessation, potentially affecting patient function, and quality of life. The development of accurate and sensitive assessment tools for CIPN is essential to enable clinical monitoring during treatment, follow-up of long-term outcomes and measurement of toxicity in clinical trials.This review examines CIPN clinical assessment scales incorporating clinician-based, composite, and patient-reported outcomes (PROs), providing a systematic review of their properties and an updated critical analysis of recommendations on current evidence for their use. This systematic review of CIPN assessment tools identified 50 papers containing 41 assessment tools, across 4 categories (common toxicity criteria; composite neurological scale; PROs; pain scale). The majority of these tools were PROs, underscoring the importance of patient-based assessment of symptoms.While there has been considerable work in the field over the past 10 years, this review highlights significant gaps, including a lack of evaluation of responsiveness and problematic neuropathic pain evaluation. There remains a need for consensus on the best available tool and the need to modify existing instruments to improve utility. K E Y W O R D S assessment, chemotherapy, CIPN, neuropathy, neurotoxicity, outcome measures 1 | INTRODUCTION Chemotherapy-induced peripheral neurotoxicity (CIPN) is a prominent adverse event of cancer treatment, leading to dose reduction and premature treatment cessation, potentially affecting patient function and quality of life. The development of accurate and sensitive assessment tools for CIPN is essential to enable clinical monitoring during treatment, follow-up of long-term outcomes and measurement of toxicity in clinical trials. As with all treatment toxicities, a balanced approach between patient report, objective examination and clinician discretion is warranted. It is likely that tailored assessment strategies will be required to facilitate appropriate assessment in different contexts ranging from routine clinical screening tools to comprehensive multimodal assessments and outcome measures in clinical trials. Assessment tools which do not require specialised equipment are most accessible for routine clinical use. While common toxicity criteria (CTC) are the most commonly utilised assessment tools for a range of cancer treatment toxicities including CIPN, validated patient-reported outcome (PRO) measures provide sensitive assessment of neuropathy symptoms and significance for the patient. Composite neurological assessments containing a combination of symptom report and neurological examination findings provide another method of CIPN evaluation. Given the importance of selecting appropriate outcome measures, including in drug development and for regulatory approval, review of the properties of CIPN assessment tools is warranted.From this search, a total of 50 papers meeting inclusion criteria wer...

show abstract

Section: Resultsmentioning

confidence: 99%

Overview and critical revision of clinical assessment tools in chemotherapy‐induced peripheral neurotoxicity

Park

Alberti

Kolb

et al. 2019

J Peripheral Nervous Sys

View full text Add to dashboard Cite

show abstract

“…VAC14 has been directly linked to neurodegeneration in animal models(20) and linked to hereditary neuropathy conditions in humans(28). The lack of clinical replication in a cohort of paclitaxel-treated breast cancer patients is perhaps due to known differences between the two taxanes, including neuropathy profile(29). Distinct genetic modifiers of cellular sensitivity to paclitaxel and docetaxel have been previously reported in in vitro models(30) and the results of cellular sensitivity experiments demonstrating that VAC14 knockdown enhances sensitivity of peripheral neurons to docetaxel but not paclitaxel for relative number of processes and relative branching, further support this hypothesis.…”

Section: Discussionmentioning

confidence: 99%

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

Hertz

Owzar

Lessans

et al. 2016

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose Discovery of single nucleotide polymorphisms (SNPs) that predict a patient's risk of docetaxel-induced neuropathy would enable treatment individualization to maximize efficacy and avoid unnecessary toxicity. The objectives of this analysis were to discover SNPs associated with docetaxel-induced neuropathy and mechanistically validate these associations in preclinical models of drug-induced neuropathy. Experimental Design A genome-wide association study was conducted in metastatic castrate-resistant prostate cancer patients treated with docetaxel, prednisone and randomized to bevacizumab or placebo on CALGB 90401. SNPs were genotyped on the Illumina HumanHap610-Quad platform followed by rigorous quality control. The inference was conducted on the cumulative dose at occurrence of grade 3+ sensory neuropathy using a cause-specific hazard model that accounted for early treatment discontinuation. Genes with SNPs significantly associated with neuropathy were knocked down in cellular and mouse models of drug-induced neuropathy. Results 498,081 SNPs were analyzed in 623 Caucasian patients, 50 (8%) of whom experienced grade 3+ neuropathy. The 1000 SNPs most associated with neuropathy clustered in relevant pathways including neuropathic pain and axonal guidance. A SNP in VAC14 (rs875858) surpassed genome-wide significance (p=2.12×10-8 adjusted p=5.88×10-7). siRNA knockdown of VAC14 in stem cell derived peripheral neuronal cells increased docetaxel sensitivity as measured by decreased neurite processes (p=0.0015) and branches (p<0.0001). Prior to docetaxel treatment VAC14 heterozygous mice had greater nociceptive sensitivity than wild-type litter mate controls (p=0.001). Conclusions VAC14 should be prioritized for further validation of its potential role as a predictor of docetaxel-induced neuropathy and biomarker for treatment individualization.

show abstract

“…Chemotherapy regimen at the time of lafutidine administration included paclitaxel plus carboplatin (TC) in 13 patients, dose-dense TC in three patients, docetaxel as maintenance chemotherapy following TC regimen in three patients, and docetaxel plus carboplatin (DC) in one patient. The median number of cycles of chemotherapy at the start of lafutidine administration was four (range, [1][2][3][4][5][6][7][8][9][10][11][12][13][14]. Three patients complained of prolonged neuropathy after having completed the chemotherapy.…”

Section: Resultsmentioning

confidence: 99%

“…Among several patient-based assessment instruments, item 1 of the PNQ was chosen for use in this study because of its adequate description of the symptoms of peripheral neuropathy and its simplicity. Assessment in combination with other measurements such as the Visual Assessment Scale (VAS) may be more appropriate for precise evaluation of peripheral neuropathy in further studies [13,14].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of lafutidine, a histamine H2-receptor antagonist, for taxane-induced peripheral neuropathy in patients with gynecological malignancies

Nagano

Sanai

Muraoka

et al. 2012

Gynecologic Oncology

View full text Add to dashboard Cite

Precise evaluation of chemotherapy-induced peripheral neuropathy using the visual analogue scale: a quantitative and comparative analysis of neuropathy occurring with paclitaxel–carboplatin and docetaxel–carboplatin therapy

Abstract: The VAS could appropriately recognize the difference in peripheral neuropathy between TC and DC. Moreover, the VAS could also catch the change in peripheral neuropathy. This result suggests that the VAS system is a useful tool for managing peripheral neuropathy.

Cited by 16 publications

References 20 publications

Overview and critical revision of clinical assessment tools in chemotherapy‐induced peripheral neurotoxicity

Overview and critical revision of clinical assessment tools in chemotherapy‐induced peripheral neurotoxicity

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

Efficacy of lafutidine, a histamine H2-receptor antagonist, for taxane-induced peripheral neuropathy in patients with gynecological malignancies

Contact Info

Product

Resources

About